Journal Mobile Options
Table of Contents
Vol. 9, No. 5, 2009
Issue release date: November 2009
Pancreatology 2009;9:670–676
(DOI:10.1159/000181179)

A Preoperative Prognostic Score for Resected Pancreatic and Periampullary Neuroendocrine Tumours

Sakka N. · Smith R.A. · Whelan P. · Ghaneh P. · Sutton R. · Raraty M. · Campbell F. · Neoptolemos J.P.
aDivision of Surgery and Oncology, School of Cancer Studies, University of Liverpool, and bDepartment of Pathology, Royal Liverpool University Hospital, Liverpool, UK

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background/Aims: To identify potential preoperative prognostic factors in resected pancreatic and periampullary neuroendocrine tumours. Methods: Clinico-pathological data for 54 consecutive patients with pancreatic or periampullary neuroendocrine tumours referred to our institution over a 10-year period were identified from a prospective database. Results: 34 patients underwent pancreatic resection (12 males, 22 females; median age 54 (IQR 44–71) years). There was a single 30-day mortality (3%). Nodal status (log rank, p = 0.652), microscopic resection margin involvement (p = 0.549) and tumour size (p = 0.122) failed to exhibit any prognostic value. Only the presence of malignant tumour characteristics was associated with poorer overall survival (p = 0.008). Analysis of preoperative parameters showed that age >60 years (p = 0.056), platelet-lymphocyte ratio >300 (p = 0.008), alkaline phosphatase levels >125 U/l (p = 0.042) and alanine aminotransferase >35 U/l (p = 0.016) were adverse prognostic factors. A risk stratification score was generated where each adverse preoperative parameter was allocated a score of 1. A cumulative score of ≤1 was defined as low risk, while a score of ≥2 was defined as high risk. Median overall survival in the high-risk group was 10.4 months, while the median survival in the low-risk group was >60 months (p < 0.001). Conclusion: Significant prognostic information can be gained from routine preoperative biochemistry and haematology results in resected pancreatic and periampullary neuroendocrine tumours. These findings merit further evaluation in a larger patient cohort.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ: Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1766–1773.
  2. Alexakis N, Neoptolemos JP: Pancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol 2008;22:183–205.
  3. Alexakis N, Connor S, Ghaneh P, Lombard M, Smart HL, Evans J, Hughes M, Garvey CJ, Vora J, Vinjamuri S, Sutton R, Neoptolemos JP: Hereditary pancreatic endocrine tumours. Pancreatology 2004;4:417–433.
  4. Jarufe NP, Coldham C, Orug T, Mayer AD, Mirza DF, Buckels JA, Bramhall SR: Neuroendocrine tumours of the pancreas: predictors of survival after surgical treatment. Dig Surg 2005;22:157–162.
  5. Oberg K, Eriksson B: Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005;19:753–781.
  6. Vagefi, Razo O, Deshpande V, McGrath DJ, Lauwers GY, Thayer SP, Warshaw AL, Fernandez-Del Castillo C: Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms. Arch Surg 2007;142:347–354.
  7. Phan GQ, Yeo CJ, Hruban RH, Lillemoe KD, Pitt HA, Cameron JL: Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg 1998;2:472–482.
  8. Solorzano CC, Lee JE, Pisters PW, Vauthey JN, Ayers GD, Jean ME, Gagel RF, Ajani JA, Wolff RA, Evans DB: Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 2001;130:1078–1085.
  9. Gullo L, Miglori M, Falconi M, Pederzoli P, Bettini R, Casadei R, Delle Fave G, Corleto VD, Ceccarelli C, Santini D, Tomassetti P: Nonfunctioning pancreatic endocrine tumours: a multicenter clinical study. Am J Gastroenterol 2003;98:2435–2439.
  10. Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF, Klimstra DS: Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate grade groups. J Clin Oncol 2002;20:2633–2642.
  11. Fendrich V, Langer P, Celik I, Bartsch DK, Zielke A, Ramaswamy A, Rothmund M: An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumours. Ann Surg 2006;244:845–853.
  12. Brown KM, Domin C, Aranha GV, Yong S, Shoup M: Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am J Surg 2005;189:278–282.
  13. Fogar P, Sperti C, Basso D, Sanzari MC, Greco E, Davoli C, Navaglia F, Zambon CF, Pasquali C, Venza E, Pedrazzoli S, Plebani M: Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas 2006;32:22–28.
  14. Jamieson NB, Glen P, McMillan DC, McKay CJ, Foulis AK, Carter R, Imrie CW: Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer 2005;92:21–23.
  15. Capella C, Heitz PU, Höfler H, Solcia E, Klöppel G: Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995;425:547–560.
  16. Kloppel G, Perren A, Heitz PU: The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification system. Ann NY Acad Sci 2004;1014:13–27.
  17. Altman DG, Lausen B, Sauerbrei W, Schumacher M: Dangers of using optimal cutpoints in the evaluation of prognostic factors. J Nat Cancer Inst 1994;86:829–835.
  18. Vittinghoff E, McCulloch CE: Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 2007;165:710–718.
  19. Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, Bentrem DJ: Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3,851 patients. Ann Surg 2008;247:490–500.
  20. Nguyen SQ, Angel LP, Divino CM, Schluender S, Warner RR: Surgery in malignant pancreatic neuroendocrine tumours. J Surg Oncol 2007;96:397–403.
  21. Kazanjian KK, Reber HA, Hines OJ: Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 2006;141:765–770.
  22. Glen P, Jamieson NB, McMillan DC, Carter R, Imrie CW, McKay CJ: Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology 2006;6:450–453.
  23. Lien YC, Hsieh CC, Wu YC, Hsu HS, Hsu WH, Wang LS, Huang MH, Huang BS: Preoperative serum albumin level is a prognostic indicator for adenocarcinoma of the gastric cardia. J Gastrointest Surg 2004;8:1041–1048.
  24. Clancy TE, Sengupta TP, Paulus J, Ahmed F, Duh MS, Kulke MH: Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Dig Dis Sci 2006;51:877–884.
  25. Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, Ghaneh P: Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 2008; Epub ahead of print.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50